South Korean biosimilar companies secure no US or EU approvals this year
AI Summary- South Korean biosimilar companies secured no US or European approvals this year.
- The US and EU approved 21 biosimilars, including nine from Indian companies and eight from Chinese companies.
- Samsung Bioepis and Celltrion are developing Keytruda biosimilars and pursuing regulatory approvals.